Ironwood Pharmaceuticals ... (IRWD)
1.90
-0.04 (-2.06%)
At close: Feb 20, 2025, 3:59 PM
1.99
4.74%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 1.9 |
| Market Cap | 304.05M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.01 |
| PE Ratio (ttm) | -190 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.08 |
| Volume | 1,129,392 |
| Avg. Volume (20D) | 3,095,193 |
| Open | 1.93 |
| Previous Close | 1.94 |
| Day's Range | 1.90 - 2.01 |
| 52-Week Range | 1.59 - 15.26 |
| Beta | undefined |
About IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...
Sector Healthcare
IPO Date Feb 3, 2010
Employees 267
Stock Exchange NASDAQ
Ticker Symbol IRWD
Website https://www.ironwoodpharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 426.32% from the latest price.
Buy 75.00%
Hold 25.00%
Sell 0.00%
Next Earnings Release
Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-38.17%
Ironwood Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
3 weeks ago
-2.11%
Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.
